Skip to content
    Cystic Fibrosis Foundation logo

    Cystic Fibrosis Foundation

    Bethesda, Maryland, United StatesFounded 1955
    www.cff.orgLinkedIn
    Biotech & Life SciencesHealthcare

    The Cystic Fibrosis Foundation is a nonprofit organization that pioneered the venture philanthropy model in biotech, investing in companies developing breakthrough treatments and cures for cystic fibrosis. Through CF Foundation Mission Ventures, it provides capital across all phases of drug development, from early-stage discovery through clinical development and commercialization.

    40% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $74.6M (across 9 rounds with reported amounts).

    Find people at Cystic Fibrosis Foundation on Goldilocks AI

    Portfolio

    10

    Fund Size

    —

    Top Stage

    Series B

    Last 12 Mo

    0

    Team

    AF

    Albert Faro, MD

    Senior Vice President and Chief Medical Officer

    ES

    Eleana Seek

    Senior Vice President and Chief Audit and Risk Officer

    HC

    Heather Culp, JD

    Senior Vice President and Chief Development Officer

    IB

    Irena Barisic

    Executive Vice President and Chief Operating and Financial Officer

    JC

    JP Clancy, MD

    Senior Vice President of Clinical Research

    KB

    Kathryn Brown

    Senior Vice President and Chief Communications and Marketing Officer

    MG

    Marin Goings

    Senior Vice President and Chief of Strategy

    MB

    Mary B. Dwight

    Senior Vice President and Chief Policy and Advocacy Officer

    MC

    Michael Cavadel, JD

    Senior Vice President and Chief Legal Officer

    MR

    Molly Riley

    Senior Vice President of Field Management

    SR

    Steven Rowe, MD

    Executive Vice President and Chief Scientific Officer

    SS

    Sue Sullivan

    Vice President of Community Partnerships

    Portfolio Breakdown

    Stage Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    10 investments
    CompanyRoundAmountDate
    SSionnaSeries C$182MJan 2024
    ViaNautis logoViaNautisSeries A$25MNov 2023
    CCarmine TherapeuticsSeries A—Oct 2022
    Carbon Biosciences logoCarbon BiosciencesSeries A$38MJun 2022
    Sionna Therapeutics logoSionna TherapeuticsSeries B$111MApr 2022
    SSalioGen TherapeuticsSeries B$115MJan 2022
    SalioGen logoSalioGenSeries B$115MJan 2022
    44DMTSeries C$75MJun 2020
    IIcagen, Inc.Unknown$7.3MJan 2018
    PPearl DiagnosticsSeed$3.5M—

    Top Co-Investors

    T. Rowe Price3 shared
    Atlas Venture2 shared
    OrbiMed2 shared
    Viking Global Investors2 shared
    Perceptive Advisors2 shared
    D1 Capital Partners2 shared
    Fidelity Management & Research Company2 shared
    RD Fund2 shared
    SymBiosis2 shared
    EPIQ Capital Group2 shared
    GordonMD Global Investments2 shared
    TPG Rise1 shared
    RA Capital Management1 shared
    4BIO Capital1 shared
    BGF1 shared
    UCB Ventures1 shared
    Origin Ventures1 shared
    Eli Lilly and Company1 shared
    SevenX Ventures1 shared
    Longwood Fund1 shared

    Last updated: 9 September 2026